The FDA has issued a Complete Response Letter for Mylan and Biocon’s pegfilgrastim biosimilar, MYL-1401H, referenced on Neulasta.
Indian drug maker Biocon announced today that the FDA has issued a Complete Response Letter (CRL) for Biocon—Mylan’s proposed pegfilgrastim biosimilar, MYL-1401H, referenced on Neulasta.
Pegfilgrastim is a long-acting version of filgrastim; while biosimilars of filgrastim are approved in the United States and in the European Union, to date, no biosimilar developer had been successful in gaining regulatory clearance in either region for the more complex long-acting drug. One of the challenges of developing pegfilgrastim has been the presence of the polyethylene glycol (PEG) molecule, which is bonded to filgrastim and slows the rate at which the drug is metabolized.
Biocon indicates that the CRL for the drug relates to “data from facility requalification activities” after recent modifications to its manufacturing plant, and that the CRL did not raise questions concerning the drug’s biosimilarity, pharmacokinetic or pharmacodynamic data, clinical data, or immunogenicity. Biocon—Mylan had previously withdrawn an application for the same drug from the European Medicines Agency (EMA) after a French National Agency for Medicines and Health Products Safety (ANSM) inspection that found 35 deficiencies—11 of them major—in Biocon’s manufacturing practices at its Bangalore manufacturing plant. While the companies plan to resubmit their application to the EMA after a re-inspection of the facility, they have not issued a statement as to when they plan to resubmit a Biologics License Application for the drug to the FDA.
Some stakeholders are hopeful that an eventual approval of a biosimilar pegfilgrastim could produce significant savings for health plans. Molly Billstein Leber, PharmD, BCPS, FASHP, and manager of medication policy and formulary management for the Yale New Haven Health System, told The Center for Biosimilars® in an e-mail, “If insurance companies will reimburse for the biosimilar product, it will be a huge cost savings to the health system. The majority of pegfilgrastim usage is outpatient, so the acceptance rate will be closely tied to reimbursement.”
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.